VYGR
Company Description
Voyager Therapeutics, Inc., a gene therapy company, focuses on the development of treatments and next-generation platform technologies. The company's lead clinical candidate is the VY-AADC, which is in open-label Phase 1 clinical trial for the treatment of Parkinson's disease. Its preclinical programs comprise VY-SOD102 for the treatment of amyotrophic lateral sclerosis; VY-HTT01 for Huntington's disease; VY-FXN01 for Friedreich's ataxia; and Tau program for the treatment of tauopathies, including Alzheimer's disease, progressive supranuclear palsy, and frontotemporal dementia, as well as for spinal muscular atrophy. The company has collaboration and license agreements with Neurocrine Biosciences, Inc., Pfizer Inc., and Novartis Pharma, A.G. for the research, development, and commercialization of adeno-associated virus gene therapy products. Voyager Therapeutics, Inc. was incorporated in 2013 and is headquartered in Cambridge, Massachusetts.
Track Record
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 40.37M | 80.00M | 250.01M | 40.91M | 37.41M | 171.13M | 104.39M | 7.62M | 10.13M | 14.22M | 17.33M | 0 |
| Net Income | (119.72M) | (65.00M) | 132.33M | (46.41M) | (71.20M) | 36.74M | (43.60M) | (88.29M) | (70.70M) | (40.19M) | (29.67M) | (16.32M) |
| EPS | -2.04 | -1.13 | 3.08 | -1.21 | -1.75 | 0.99 | -1.14 | -2.75 | -2.64 | -1.59 | -7.08 | -1.11 |
| Free Cash Flow | (135.06M) | (18.83M) | 74.66M | (15.00M) | (55.13M) | (108.81M) | 40.95M | (20.19M) | (65.33M) | (47.51M) | N/A | N/A |
| FCF / Share | -2.30 | -0.33 | 1.74 | -0.39 | -1.46 | -2.93 | 1.14 | -0.63 | -2.44 | -1.88 | N/A | N/A |
| Operating CF | (132.47M) | (15.31M) | 77.92M | (12.51M) | (53.52M) | (96.72M) | 48.67M | (15.89M) | (61.35M) | (42.48M) | N/A | N/A |
| Total Assets | 252.28M | 393.05M | 351.28M | 159.36M | 193.85M | 261.58M | 354.76M | 177.03M | 184.48M | 189.57M | N/A | N/A |
| Total Debt | 36.50M | 43.73M | 20.29M | 23.13M | 44.18M | 47.61M | 34.17M | 0 | 0 | 0 | N/A | N/A |
| Cash & Equiv | 65.30M | 71.37M | 68.80M | 98.96M | 117.43M | 104.44M | 86.04M | 46.86M | 31.53M | 36.64M | N/A | N/A |
| Book Value | 196.08M | 299.76M | 236.32M | 59.02M | 95.06M | 154.32M | 99.51M | 46.45M | 134.05M | 135.92M | N/A | N/A |
| Return on Equity | -0.61 | -0.22 | 0.56 | -0.79 | -0.75 | 0.24 | -0.44 | -1.90 | -0.53 | -0.30 | N/A | N/A |
| Metric | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 2.59M | 15.34M | 13.37M | 5.20M | 6.47M | 6.28M | 24.63M | 29.58M | 19.52M | 90.06M | 4.61M | 4.85M |
| Net Income | (27.94M) | (27.43M) | (27.89M) | (33.38M) | (31.02M) | (34.49M) | (9.04M) | (10.14M) | (11.33M) | 56.40M | (25.90M) | (22.21M) |
| EPS | -0.47 | -0.47 | -0.47 | -0.57 | -0.53 | -0.59 | -0.16 | -0.18 | -0.20 | 1.28 | -0.59 | -0.51 |
| Free Cash Flow | (33.43M) | (30.89M) | (31.25M) | (34.37M) | (38.55M) | (14.68M) | (28.23M) | (32.55M) | 56.63M | (24.52M) | (21.83M) | (2.04M) |
| FCF / Share | -0.56 | -0.53 | -0.53 | -0.59 | -0.66 | -0.25 | -0.49 | -0.56 | 0.99 | -0.56 | -0.50 | -0.05 |
| Operating CF | (33.42M) | (30.26M) | (31.05M) | (33.26M) | (37.90M) | (14.53M) | (27.97M) | (31.58M) | 58.77M | (23.76M) | (21.05M) | (835,000) |
| Total Assets | 219.32M | 252.28M | 288.31M | 322.10M | 353.24M | 393.05M | 426.04M | 436.23M | 469.59M | 351.28M | 294.65M | 315.54M |
| Total Debt | 34.57M | 36.50M | 38.37M | 40.20M | 42.00M | 43.73M | 45.35M | 46.94M | 47.94M | 20.29M | 21.02M | 21.74M |
| Cash & Equiv | 43.31M | 65.30M | 45.12M | 43.94M | 74.75M | 71.37M | 112.53M | 76.13M | 143.08M | 68.80M | 65.27M | 244.29M |
| Book Value | 173.67M | 196.08M | 219.82M | 243.94M | 272.70M | 299.76M | 330.31M | 335.42M | 340.89M | 236.32M | 176.22M | 199.03M |
| Return on Equity | -0.16 | -0.14 | -0.13 | -0.14 | -0.11 | -0.12 | -0.03 | -0.03 | -0.03 | 0.24 | -0.15 | -0.11 |
